ON THE BREEDING OF THE WHITE-RUMPED SWIFT (APUS CAFFER CAFFER) IN GATOOMA

Crawford, R. J. M., Cooper, J. &; Shelton, P. A. 1982. Distribution, population size, breeding and conservation of the Kelp Gull in southern Africa. Ostrich 53:164:177.

The Kelp Gull Lams dominicanus in Africa occurs coastally between Luanda, Angola and Delagoa Bay, Moçmbique. It breeds between Cape Cross Lagoon, South West Africa/Namibia and Riet River, eastern Cape, South Africa. Censuses of nests and breeding birds at all known southern African breeding localities in the period 1976–1981 indicated that 11 199 pairs bred at 52 localities; 79.5% of this population occurred in South Africa, 57,1% in the Saldanha Bay to Dassen Island region, southwestern Cape. Of the breeding pairs 83% occurred on offshore islands and rocks. Colony size at islands is related to their surface area andMayalso be influenced by food availability and the level of human disturbance. The species breeds in a wide variety of habitats ranging from cliffs and rock stacks to wooden platforms, lowlying vegetation among sand dunes and estuarine sandbars. Any available material is used in the construction of nests, whichMaybe as dense as 4/m² Clutch size is 2–3 eggs. In 1978 breeding took place earlier in South Africa than in South West Africa/Namibia. 92% of the population breeds m sites which are legally protected. Kelp Gulls have decreased or increased in numbers at some breeding localities but there is no clear overall trend. Any increases in colony size near urban areasMayresult in added airstrike hazards.     

Multicenter evaluation of the phosphorylcholine-coated biodivYsio stent in short de novo coronary lesions: The SOPHOS study

AIMS: The BiodivYsio trade mark stent (Biocompatibles Ltd, Farnham, UK) is coated with a phosphorylcholine (PC)-containing copolymer to confer biocompatibility. The SOPHOS (Study Of PHosphorylcholine coating On Stents) study was designed to assess the safety and efficacy of this novel coronary stent and by indirect comparison to indicate equivalence with other formal stent studies. METHODS AND RESULTS: Patients with angina and a single short (#x2A7F;12 mm) de novo lesion in a native coronary artery of >/=2.75 mm diameter were included. A total of 425 patients were allocated in 24 centers. Clinical data were collected at one-, six- and nine-month follow-up. Angiography was performed before and after the stent implantation. In addition, in the first 200 patients (SOPHOS A) angiography was routinely performed at six months. The following 225 patients (SOPHOS B) were merely followed up clinically. The primary end-point of the study, the six-month MACE-rate (MACE = Major Adverse Cardiac Events) was 13.4% (two cardiac death; five Q-wave/nine non-Q-wave myocardial infarctions (MI); nine CABG and 32 target lesion revascularization (TLR), which is similar to the calculated 15% MACE-rate in comparable reference studies. Secondary end-points included among others restenosis at six months in the SOPHOS A population. The target vessel diameter was 2.98 +/- 0.48 mm. Minimal lumen diameter pre/post procedure and at follow-up was 1.00 +/- 0.32, 2.69 +/- 0.37, 1.91 +/- 0.71 mm, respectively. The binary restenosis rate (>/=50% diameter stenosis at follow-up) was 17.7%. CONCLUSION: The coronary BiodivYsio stent is safe and effective as a primary device for the treatment of native coronary artery lesions in patients with stable or unstable angina pectoris. Clinical and angiographic results are in the statistical range of equivalence with comparable studies with other current stents.     

A Glycolipid Adjuvant, 7DW8-5, Enhances CD8+ T Cell Responses Induced by an Adenovirus-Vectored Malaria Vaccine in Non-Human Primates

A key strategy to a successful vaccine against malaria is to identify and develop new adjuvants that can enhance T-cell responses and improve protective immunity. Upon co-administration with a rodent malaria vaccine in mice, 7DW8-5, a recently identified novel analog of α-galactosylceramide (α-GalCer), enhances the level of malaria-specific protective immune responses more strongly than the parent compound. In this study, we sought to determine whether 7DW8-5 could provide a similar potent adjuvant effect on a candidate human malaria vaccine in the more relevant non-human primate (NHP) model, prior to committing to clinical development. The candidate human malaria vaccine, AdPfCA (NMRC-M3V-Ad-PfCA), consists of two non-replicating recombinant adenoviral (Ad) vectors, one expressing the circumsporozoite protein (CSP) and another expressing the apical membrane antigen-1 (AMA1) of Plasmodium falciparum. In several phase 1 clinical trials, AdPfCA was well tolerated and demonstrated immunogenicity for both humoral and cell-mediated responses. In the study described herein, 25 rhesus macaques received prime and boost intramuscular (IM) immunizations of AdPfCA alone or with an ascending dose of 7DW8-5. Our results indicate that 7DW8-5 is safe and well-tolerated and provides a significant enhancement (up to 9-fold) in malaria-specific CD8+ T-cell responses after both priming and boosting phases, supporting further clinical development.     

Tyrosine-specific MAPK phosphatases and the control of ERK signaling in PC12 cells

Background

Spatio-temporal control of extracellular signal-regulated kinase (ERK) activity, a critical determinant of the cell's response to growth factors, requires timely dephosphorylation of its regulatory tyrosine and/or threonine residue by MAPK phosphatases. We studied the physiological role of kinase interaction motif (KIM)-containing protein tyrosine phosphatases (PTPs) in the control of EGF- and NGF-induced ERK activity in neuroendocrine PC12 cells.

Results

We found a single KIM-containing PTP to be endogenously expressed in rat PC12 cells: the transmembrane PTPRR isoform termed PCPTP1. Protein knock-down of PCPTP1, or fourfold overexpression of its mouse orthologue, PTPBR7, left EGF- and NGF-induced ERK1/2 activity in PC12 cells unaltered. Ectopic expression of cytosolic PTPRR isoforms, however, resulted in reduced EGF-induced ERK1/2 activity, an effect that was dependent on the phosphatase activity and the KIM-domain of these PTPs.

Conclusion

The finding that robust changes in tyrosine-specific MAPK phosphatase expression levels have minor effects on temporal ERK1/2 activity control in PC12 cells suggests that dual-specificity MAPK phosphatases may act as major regulators of growth factor-induced ERK1/2 signaling in these cells.     

Rapid decline of host defences in response to reduced cuckoo parasitism: behavioural flexibility of reed warblers in a changing world

On Wicken Fen and nearby watercourses eastern England, parasitism by cuckoos, Cuculus canorus, declined from 26% and 16% of reed warbler (Acrocephalus scirpaceus) nests in 1985 and 1986, respectively, to 2 to 6% of nests in 1995 to 1997, owing to a decline in cuckoos. Experiments with model eggs showed that over this 12-year period there was a marked decline in host rejection of non-mimetic eggs, from rejection at 75% of reed warbler nests in 1985 to 1986 to 25%, nests in 1997. Calculations suggest that this decline in host defences is too rapid to reflect only genetic change, and is more likely to be the outcome of adaptive phenotypic flexibility. Two other results show flexibility in host responses. First, there was a seasonal decline in rejection, which accompanied the seasonal decline in parasitism. Second, although rejection did not vary with proximity to a naturally parasitized nest within the 3.4km² of Wicken Fen and its surrounds, there was no rejection at a small unparasitized population 11km away. Flexible host defences will be advantageous when there are costs of rejection as well as short-term temporal changes and small-scale geographical variation in parasitism rate. Other recent studies reporting changes in host defences may also reflect phenotypic flexibility rather than evolutionary change.